CV Stock Analysis: Buy, Sell, or Hold?
CV - CapsoVision, Inc. Common Stock
$6.29
0.30 (5.01%)
▲
5d:
-4.84%
30d:
-13.12%
90d:
+0.64%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 13, 2026
30d
Get Alerted When CV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CV is currently trading at $6.29, which is considered oversold relative to its 30-day fair value range of $6.30 to $7.42.
Technical Outlook: Technically, CV is in a uptrend. The price is currently testing key support at $6.44. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: CV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+66.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CV is in a uptrend. The price is currently testing key support at $6.44. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: CV has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+66.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.30 -
$7.42
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- BULLISH: Trading 66.9% below Wall St target ($10.00)
Trading Range Analysis
30-Day Trading Range
$6.30 -
$7.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.44
Resistance Level
$7.80
Current Trend
Uptrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.26
Wall Street Target
$10.00
(+66.9%)
Revenue Growth (YoY)
0.3%
Profit Margin
-198.9%
Share & Embed Analysis
Last updated: July 13, 2026 12:43 PM ET
Data refreshes hourly during market hours. Next update: 1:43 PM
Data refreshes hourly during market hours. Next update: 1:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 66 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 64 BUY |